Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
AssigneeUniversity of North Texas Health Science Center at Fort Worth
InventorsPorunellor A. Mathew, Kent Boles
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid molecules encoding cell surface receptors on immune cells and the characteristic peptides that comprise these receptors. More specifically, the present invention concerns the use of synthetic and recombinant peptides comprising natural killer (“NK”) cell surface receptors. The synthetic and recombinant peptides are used to generate monoclonal antibodies that bind a specific NK cell surface receptor called CS1. The binding of the monoclonal antibody to the NK cell surface receptor leads to NK cell activation. In a particular embodiments of the present invention, the monoclonal antibodies are utilized in a method that inhibits the growth of tumor cells.
Claims37
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a proteinaceous molecule or biological equivalent, wherein the encoded proteinaceous molecule or biological equivalent has a predicted peptide sequence homologous to a subset of a CD2 family of receptors, a predicted length of about 335 amino acids;
- a predicted intracellular domain of about 85 amino acid residues;
- a predicted extracellular domain of about 225 amino acid residues;
- and a predicted single transmembrane domain of about 25 amino acid residues.
An isolated proteinaceous molecule or biological equivalent comprising a synthetic or recombinant polypeptide of a cell surface receptor that is homologous to a subset of a CD2 family of receptors with a predicted length of about 335 amino acids;
- a predicted intracellular domain of about 85 amino acid residues;
- a predicted extracellular domain of about 225 amino acid residues;
- and a predicted single transmembrane domain of about 25 amino acid residues.
A monoclonal antibody produced by:
- (a) injecting an animal with a synthetic or recombinant proteinaceous molecule or biological equivalent of a natural killer cell surface receptor to produce an immunized animal;
- (b) harvesting spleen cells from the immunized animal to give harvested spleen cells;
- (c) fusing the harvested spleen cells with an immortal cell line to produce a fusion cell line;
- (d) screening the fusion cell line to identify cells that specifically produce a monoclonal antibody with affinity toward the synthetic or recombinant proteinaceous molecule or biological equivalent;
- and
- (e) selecting and expanding the fusion cell line only with cells that specifically produce the monoclonal antibody.
A fusion cell line produce by:
- (a) injecting an animal with a synthetic or recombinant proteinaceous molecule or biological equivalent of a natural killer cell surface receptor to produce an immunized animal;
- (b) harvesting spleen cells from the immunized animal to give harvested spleen cells;
- (c) fusing the harvested spleen cells with an immortal cell line to produce a fusion cell line;
- (d) screening the fusion cell line to identify cells that specifically produce a monoclonal antibody with affinity toward the synthetic or recombinant proteinaceous molecule or biological equivalent;
- and
- (e) selecting and expanding the fusion cell line only with cells that specifically produce the monoclonal antibody.
Dependencies are inferred from the claim text.